These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 6185342

  • 41. Chemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture.
    Bonadonna G.
    Cancer Res; 1982 Nov; 42(11):4309-20. PubMed ID: 6181867
    [Abstract] [Full Text] [Related]

  • 42. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
    Brusamolino E, Orlandi E, Morra E, Castelli G, Pagnucco G, Livraghi A, Astori C, Santagostino A, Lazzarino M, Bernasconi C.
    Ann Oncol; 1994 Nov; 5 Suppl 2():53-7. PubMed ID: 7515648
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
    Andrieu JM, Colonna P.
    J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
    [No Abstract] [Full Text] [Related]

  • 46. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.
    Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F.
    J Clin Oncol; 1987 Jan; 5(1):27-37. PubMed ID: 2433409
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Coser P.
    J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. ABVD versus MOPP: which is better?
    Rosenberg SA.
    J Clin Oncol; 1987 Jan; 5(1):7. PubMed ID: 2433410
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience.
    Bonadonna G, Santoro A, Gianni AM, Viviani S, Siena S, Bregni M, Zucali R, Lombardi F, Bonfante V, Gianni L.
    Ann Oncol; 1991 Jan; 2 Suppl 1():9-16. PubMed ID: 1710489
    [Abstract] [Full Text] [Related]

  • 59. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG, Schoppe WD, Fuchs R, Pflüger KH, Loeffler M, Diehl V.
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [Abstract] [Full Text] [Related]

  • 60. [Improved survival rates in Hodgkin's disease].
    Hayabuchi N, Jingu K, Miyoshi M, Hirata H, Masuda K, Shibuya T, Nishimura J, Komiyama S, Ishii E, Kikuchi M.
    Gan No Rinsho; 1988 Apr; 34(5):698-704. PubMed ID: 2455073
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.